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7Introductory note
Three in-depth reviews of topical interest are published as ’Selected issues’ in conjunction with the annual report each year. 
These selected issues are based on information provided to the EMCDDA by the EU Member States and candidate countries 
and Norway (participating in the work of the EMCDDA since 2001) as part of the national reporting process.
The three selected issues for 2007 are:
• Drugs and driving;
• Drug use and related problems among very young people (under 15 years old);
• Cocaine and crack cocaine: a growing public health issue.
Online versions of the 2007 selected issues (in English) and summaries (in 23 languages) are available at 
http://issues07.emcdda.europa.eu
The national reports of the Reitox focal points are available on the EMCDDA website 
(http://www.emcdda.europa.eu/?nnodeid=435).
The 2007 ‘Annual report on the state of the drugs problem in Europe’ is available in 23 languages and may be found at: 
http://annualreport.emcdda.europa.eu
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Introduction
As the use of illicit drugs increased towards the end of 
the 20th century, most noticeably among young adults, 
so too did concern over the effects of such substances on 
the driving population as illicit drugs affect various motor 
control and perception skills, as well as behaviour and 
attitudes to risk. Studies designed to measure the prevalence 
of drug use among drivers were largely based on the 
results of toxicological analyses, and therefore focused on 
groups of drugs categorised according to their molecular 
structure, generally opioids, cannabis, benzodiazepines, 
amphetamines and cocaine, although other classes, such as 
antihistamines, antidepressants and other synthetic drugs, 
also emerged.
However, as the number of such studies grew, it became 
clear that illicit drugs were not the only psychoactive 
substances used by drivers: a significant number were 
found to have psychoactive medicines in their bloodstream, 
including opioid painkillers such as codeine, antidepressants 
and sedatives. By the end of the 1990s, it was becoming 
increasingly clear that road traffic safety depended on 
controlling consumption not only of illicit substances such as 
cannabis and amphetamines, but also of certain medicines 
(whether legally prescribed or not). In 1999, a study of drug 
use among drivers in different European countries concluded 
that the prevalence of drug use was probably in the range of 
1 % to 5 % for illicit drugs and of 5 % to 15 % for licit drugs. 
The most commonly used medicines were benzodiazepines, 
which were prioritised within the Certified project as one of 
the substances associated with the highest relative accident 
risk — higher than that of cannabis (Verstraete, 2003).
Since then, considerable European and world research 
has addressed the issue. An EMCDDA literature review in 
1999 summarised the information then available on the 
effects of drug use on driving, and this has been updated in 
2007. Comprehensive questionnaires from the Pompidou 
Group in 1999, 2002 and 2005 on drugs and road safety 
provided material for discussions at seminars hosted by that 
organisation. The International Conference on Alcohol, Drugs 
and Traffic Safety (ICADTS) is held every 2 to 3 years, and 
at each of the last two conferences, in 2004 and 2007, over 
200 papers were presented. EU projects have also been 
carried out: Rosita and Rosita–2 examined roadside drug 
testing devices, Certified assessed which drugs carry the 
highest risk of impairment and Immortal studied various types 
of impairment and their related aspects (laws, epidemiology, 
accident risk, testing) and their effects on driver licensing.
Coordinated by the European Commission’s Directorate-
General for Energy and Transport, the EU road safety 
action programme 2003–10 (COM(2003)311, s.5.1.1) 
encourages continuation of work on the effects of drugs and 
medicines, with appropriate classification and labelling 
of medicines that affect driving ability. Meanwhile, the 
Council Resolution of 27 November 2003 on combating the 
impact of psychoactive substances use on road accidents 
recommends increased epidemiological monitoring, the 
exchange of information on best practice by providing 
information to the EMCDDA, targeted prevention campaigns 
and appropriate measures against drivers found to be under 
the influence of psychoactive substances. The Commission 
expert group on drugs, medicines and driving has already 
made various recommendations and continues to study the 
matter. The EU drugs action plan 2005–08 looks at health 
risks in specific situations, such as driving under the influence 
of drugs (paragraph 24). Finally, the European Commission 
is co-financing project DRUID (Driving under the influence 
of drugs, alcohol and medicine) from 2006 to 2010. The 
objective of this project is to provide scientific support to the 
EU transport policy to reach the 2010 road safety target. The 
consortium comprises 37 partners from 18 Member States 
and Norway. The total cost of the project is EUR 23 933 860 
and the EC contribution is EUR 18 932 265 (1).
In the light of the prevalence findings and other research, the 
EMCDDA chose to study countries’ experiences of people 
driving after taking (a) cannabis and (b) benzodiazepines, 
examining the similarities and the differences between them. 
The responses were then analysed regarding legislation, law 
enforcement and prevention, and differences between the 
two substances were identified whenever possible.
(1)
(1) http://www.druid-project.eu
10
EMCDDA 2007 selected issue
Situation analysis
There are several methods of assessing the relation 
between drug use and driving, but they largely fall into two 
groups: experimental studies and epidemiological studies. 
Experimental studies aim to assess impairment caused by 
drugs consumption through performance tests (measure of 
effects), whereas epidemiological studies estimate either the 
prevalence or the risk associated with drug use.
Prevalence studies aim to determine the proportion of the 
general population driving under the influence of drugs 
(roadside surveys) or the proportion of a subset of drivers 
under the influence of drugs (drivers suspected of driving 
under the influence of drugs and/or alcohol or drivers 
injured, killed or involved in a traffic accident). Risk 
assessment investigates the risk associated with driving under 
the influence of drugs; accident risk studies estimate the risk 
of being involved in a traffic accident whereas responsibility 
studies investigate the risk of being responsible for a traffic 
accident.
Taking all of the above research as a starting point, countries 
were asked to supply any more recent statistics on drug 
prevalence in drivers, with the aim of observing how and 
where cannabis and benzodiazepines were found, and at 
what levels. Unfortunately, in the sphere of drugs and driving, 
this type of prevalence study is greatly influenced by the 
legislation of the country. For this reason, studies carried out 
in the different European countries to gauge the prevalence 
have taken a variety of forms. Therefore, before examining 
these as a whole, the reader should keep three main caveats 
in mind:
• First, the results of the studies quoted are not scientifically 
comparable. As well as differing in general study design, 
methodologies and sample groups, they are likely to vary 
in terms of the type of biological sample analysed (e.g. 
blood, urine, saliva, sweat, even hair) and the cut-off 
levels of drug considered significant.
• Second, samples are rarely, if ever, truly representative 
of the general driving population. Random roadside 
testing carried out at all times of the day and night and 
applied to all types of drivers (including commercial 
drivers) in various different locations in the country might 
be sufficient to give a conclusive picture. However, in 
practice, study samples are not usually so comprehensive.
• Finally, it should be remembered that the identification of 
drug metabolites in urine does not necessarily mean that 
a driver was under the influence of the drug at the time 
of sampling: metabolites can be detected up to one week 
after consumption. Prevalence results from surveys that 
measure such metabolites in urine should be interpreted 
accordingly.
Prevalence studies
The aim of this section is not to compare prevalence by 
country but to determine if cannabis and benzodiazepines 
are indeed the two most prevalent substances used in Europe 
and whether one is more prevalent than the other. For this 
reason, studies that reported on only one of these two drugs 
have generally been excluded.
Tests may vary in setting — at the roadside, in hospitals or 
post-mortem — as well as in form and in the control groups. 
Random roadside tests aim to give a picture of the 
percentage of the general driving population who are under 
the influence, but the study methods used may nevertheless 
give unrepresentative samples and may be hampered by 
legal obstacles in some countries. Testing on suspicion will 
clearly result in considerably higher prevalence estimates 
than random testing. Further, if the suspicion is of drug use, 
i.e. following a negative alcohol test with a breathalyser, 
the rates will be higher than for pre-breathalyser suspicion 
of intoxicated driving (alcohol or drug use). Testing of killed 
or injured drivers may also be undertaken after an accident, 
although a driver who is injured is likely to be in a far more 
severe accident than a driver who causes injury (for example, 
to a pedestrian or cyclist), when the driver may remain 
unhurt.
The following are the results of various studies, grouped 
by the type of sample tested. In this report only controlled 
drugs are considered, focusing on the relative prevalence of 
cannabis and benzodiazepines, but it should be assumed 
that alcohol is the most prevalent substance detected among 
drivers on European roads.
Random roadside tests
Only three countries reported studies involving random 
roadside testing. The studies generally agree that cannabis 
and benzodiazepines are the two most prevalent controlled 
substances detected in drivers, but vary regarding which is 
the most prevalent.
A roadside study in Germany in the mid-1990s tested 
3 027 saliva samples from drivers, of which 2.7 % were 
positive for benzodiazepines and 0.6 % were positive for 
cannabinoids — the latter showing a similar prevalence 
to opioids (0.6 %) and barbiturates (0.6 %) (Krüger et al., 
2000). In Denmark, a study in Holstebro in 2000 also tested 
saliva samples, with 0.7 % of the 1 000 drivers stopped 
testing positive for cannabis and 0.6 % testing positive 
for benzodiazepines (above 0.3 % who were positive for 
opioids) (Behrensdorff and Steentoft, (2002).
In the Netherlands, a study carried out between 2000 and 
2004 in one police district collected blood and/or urine 
samples from a random roadside sample of 3 799 motorists 
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as a control group for comparison with 184 severely 
injured drivers. Excluding alcohol, cannabis (4.5 %) and 
benzodiazepines (2.1 %) were the most prevalent substances 
in the roadside sample.
Subsets of drivers
On suspicion
Among samples taken from drivers stopped on suspicion 
of drug use, cannabis and benzodiazepines are again 
generally the most prevalent substances. Benzodiazepines 
were the most frequently found drug in studies in 
Luxembourg, Finland, the United Kingdom and Norway, 
although in three of these countries the second most prevalent 
substance was not cannabis. In Luxembourg, from 2001 to 
2002, a study analysed blood samples from 198 drivers 
whose blood alcohol concentration had already been 
measured. Benzodiazepines were detected in 10.6 % of 
cases and cannabis in 10.1 % of cases (Wennig, 2005).
In Finland in 2005, examination of 3 420 drivers suspected 
of drug use identified benzodiazepines as the most common 
group of substances, being detected in 59 % of samples. 
The main benzodiapezines identified were diazepam, 
alprazolam, temazepam, oxazepam and clonazepam. 
Amphetamine was found in 49 % of samples and cannabis 
in 22 %. Similarly, in Norway, among drivers apprehended 
on suspicion of drug use, the most frequently detected 
medicinal drugs were benzodiazepines, represented by 
diazepam, flunitrazepam, nitrazepam and clonazepam. 
Benzodiazepines were also detected more frequently than 
any illicit substance; between 2000 and 2005, 45 to 
50 % of all blood samples analysed tested positive for 
benzodiazepines, compared with 30 to 35 % for both 
cannabis and amphetamine.
In the United Kingdom, among 166 blood samples from 
drivers suspected by police of being under the influence of 
drugs, benzodiazepines were the most frequently found drug 
(primarily diazepam in 101 samples), followed by opioids 
and then cannabinoids. Fifty blood samples (30 %) were 
positive for cannabinoids, although the active component of 
cannabis, THC, was present in only 18 of them. Polydrug use 
was evident in 86 (52 %) of the blood samples analysed; of 
these, 71 included diazepam and 51 were a benzodiazepine 
and opioid combination (Oliver et al., 2006).
By contrast, cannabis was more prevalent than 
benzodiazepines in studies conducted in Germany, Ireland, 
Latvia and Slovenia. In Germany, in 2002, a study of 
1 199 drivers suspected of driving under the influence 
of alcohol found cannabis in 5.3 % of the drivers and 
benzodiazepines in 1.7 % (higher than amphetamines, 
1.3 %) (EMCDDA, in press). In Slovenia, a study of 
3 602 drivers suspected of drug consumption between 
1994 and 2001 found cannabis in 35.7 % of the drivers 
and benzodiazepines in 8.2 %; in the same study 15.1 % 
of the drivers tested positive for opioids (EMCDDA, in 
press). In Ireland, in 2000 and 2001, 2 000 blood and 
urine samples taken from drivers nationwide suspected of 
intoxicated driving were analysed (Fitzpatrick et al., 2006). 
Among drivers below the legal limit for alcohol (n = 1 000), 
20.9 % and 9 % tested positive for cannabinoids and 
benzodiazepines, respectively, whereas among drivers over 
the legal limit for alcohol (n = 1 000) the corresponding 
figures were 5.5 % and 3.4 %. The next most prevalent 
drug was methamphetamine, with positive samples being 
found in 9 % of drivers under the limit for alcohol and 2 % of 
drivers over the limit. In Latvia, 383 drivers detained during 
2005 for driving under the influence of addictive substances 
showed evidence of using a combination of drugs. The most 
frequent combination was amphetamines and cannabis, but 
combinations including benzodiazepines were also often 
detected.
In Sweden, in 2000, approximately 29 % of 3 809 blood 
samples taken from drug-driving suspects contained THC 
and about 20 % contained diazepam. In 2001, THC was 
found in 25 % of 4 651 blood samples, while about 19 % 
contained diazepam. In 2002, the percentage for THC 
was again 29 % from 5 051 samples, while diazepam 
continued to decline to 14.6 % (Jones, 2005). In an 
analysis of 15 707 cases of suspected driving under the 
influence of drugs (DUID) in the period 2001–03, the most 
common substance found was amphetamines, identified 
in approximately 56 % to 61 % of all DUID suspects. The 
second most frequently encountered illicit drug was THC, 
found in about 25 % to 30 % of cases. Benzodiazepines 
were also common, mainly diazepam (16 % to 18 %) and 
flunitrazepam (6 % to 10 %).
After accidents/injury/damage or in hospital
In four studies of drivers following accidents or injury, 
the two most common substances found were cannabis 
and benzodiazepines. The prevalence of cannabis and 
benzodiazepines was equal in one study, while in three 
studies the prevalence of cannabis was higher.
In Denmark, saliva samples from 330 drivers injured in traffic 
accidents were analysed. Cannabis and benzodiazepines 
were the most common substances detected, with rates of 
3.3 % and 3.0 % respectively (compared with opioids at 
1.8 % and cocaine at 0.6 %) (Bernhoft et al., 2005).
In France, a study in 2000 (Kintz et al., 2000) examined 
198 drivers involved in injury-causing accidents as part 
of the European Rosita project. THC was found in 9.6 % 
of blood samples and benzodiazepines in 6.1 %. These 
were the most common substances (the next most common 
12
EMCDDA 2007 selected issue
was codeine, found in 1.5 %). A study in Luxembourg 
in 1999–2002 also looked at samples from 481 drivers 
involved in traffic accidents and suspected of driving under 
the influence of drugs. Among the positive samples, the two 
most common drug classes were cannabinoids (39.9 %) 
and benzodiazepines (26.2 %). In Greece, a study of 
2 712 drivers involved in accidents between 1995 and 
2002 found rates of 4.0 % for both cannabinoids and 
benzodiazepines, just above the rate of 3.7 % for opioids 
(Maravelias, 2003).
Only one hospital study, a multicentre study in France (Mura 
et al., 2003), was reported. Blood samples from 900 drivers 
involved in an injury-causing accident and subsequently 
hospitalised were compared with blood samples from 
900 patients hospitalised for other reasons. The most 
prevalent drug in the drivers was benzodiazepines, being 
found in 14 % of samples (compared with 12.6 % in the 
control group); 10 % of the drivers tested positive for THC 
compared with 5 % of the control group.
In Austria, among 269 people who had been admitted 
to hospital after a road traffic accident, 27.5 % of 
plasma samples tested positive for alcohol, 5.2 % for 
benzodiazepines and 1.9 % for both. Cannabis was not 
tested in the study. In all cases plasma concentrations 
of benzodiazepines were within the subtherapeutic or 
therapeutic range. Evaluation of the severity of injuries 
revealed that polytrauma was significantly more common 
among those whose plasma sample was positive for 
benzodiazepines.
Drivers killed in road accidents
Of the eight European studies of drivers killed, four found 
benzodiazepines to be the most common class of drug 
present, compared with two in which cannabis was found to 
be more prevalent. Two studies found other substances to be 
the most prevalent.
In the Czech Republic, out of 633 drivers killed in traffic 
accidents in the period 2003–05, the most common 
substances found, after alcohol, were benzodiazepines 
(3.0 %) and THC (2.4 %), followed by stimulants (1.9 %). In 
one region, Southern Bohemia, a study was carried out in 
1998–2005 on a sample of 412 drivers who died in traffic 
accidents (338 of whom were subjected to toxicological 
examination). Benzodiazepines were found in five (1.5 %) 
and THC was detected in three (0.9 %) (V. Mravčík, F. Vorel 
and T. Zábranský, unpublished observations).
A study in five Nordic countries of drivers who died within 
24 hours of an accident in 2001–02 aimed to investigate 
the prevalence of alcohol and other drugs using the same 
protocol, to enable comparison, and with a focus on single-
vehicle accidents (Christophersen, 2006). The countries 
involved were Denmark, Finland, Iceland, Norway and 
Sweden. Overall, toxicological analysis was performed in 
more than 70 % of the cases, except in Denmark. In Norway, 
from a total of 243 drivers killed in accidents during the 
study period, benzodiazepines were detected almost as 
often as alcohol (21.4 % and 22.2 % respectively). THC 
and amphetamines were found in 10.5 % and 10.1 % of 
drivers respectively. Drivers killed in single-vehicle accidents 
were studied during 1989–90 (n = 79) and 2001–02 
(n = 92). The most frequently detected substances were 
alcohol, benzodiazepines (23.9 %; primarily diazepam, 
flunitrazepam), THC (15.2 %) and amphetamines. In Finland, 
427 analyses were performed on a total of 463 deceased 
drivers and, as in Norway, benzodiazepines were the most 
prevalent drugs. Cannabinoids were found in urine samples 
in seven cases (1.6 %), whereas benzodiazepines were 
detected in blood in 37 cases (8.6 %) (E. Vuori, personal 
communication). In Sweden, the study was extended for an 
additional year, and results are for the period 2000–02. 
Out of 920 drivers killed in road accidents during this 
period, blood and urine samples from 855 subjects were 
toxicologically tested (Holmgren et al., 2005). Excluding 
alcohol, amphetamines were the most common substance 
found throughout the period, with a prevalence of 
5.1 %, followed by benzodiazepines at 4.6 % and 
cannabis at 3.7 %.
In two other studies of drivers killed, cannabis was the most 
prevalent drug found. Among blood samples from 458 fatally 
injured drivers in northern Greece in the period 1999–2002, 
4.3 % tested positive for THC and 3.3 % for opioids, with 
1.3 % testing positive for benzodiazepines. In the United 
Kingdom, the Transport Research Laboratory investigated 
the presence of drugs in 1 184 road traffic fatalities between 
1985 and 1987, and then again between 1996 and 1999. 
The proportion testing positive for cannabis increased 
from 2.6 % to 11.9 %, while the corresponding figure for 
medicinal drugs was stable at 5.5 %.
As an exception to the above pattern (other than as 
reported for Sweden in the multicountry study), a study of 
5 745 drivers killed in the period 1991–2000 in Spain 
revealed that 5.2 % had consumed cocaine, 3.4 % 
benzodiazepines, 3.2 % opioids and 2.2 % cannabis (Del 
Río et al., 2002). Although these two studies again show 
the prevalence of benzodiazepines to be higher than that of 
cannabis, what is striking is the relatively high prevalence of 
cocaine in the Spanish sample; the study authors themselves 
wrote, ‘We can find no explanation for this greater frequency 
of cocaine with respect to cannabis’.
Characteristics of drug drivers
Available demographic findings universally suggest that 
cannabis-using drivers are most likely to be young men. 
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Despite the use of different age groupings, the predominant 
age of cannabis users (18–24 in the Netherlands, 
under 27 in France, 22–44 in Denmark), can generally 
be described as young. In contrast, survey results from 
Denmark, Ireland, Luxembourg and the Netherlands suggest 
that benzodiazepine users who drive are more likely to 
middle-aged (in the Netherlands and Denmark the results 
identified them as middle-aged or even elderly drivers). 
Benzodiazepine users are also more likely than cannabis 
users to be female.
These findings appear to be in line with general population 
surveys and EMCDDA data showing that young men are the 
most likely group to take drugs, and other statistical evidence 
of the young male as a risk-taker. Although there may be a 
certain data bias in ‘suspicion’ statistics, in that traffic officers 
are more likely to suspect young male drivers of having 
taken drugs and so test them more, analyses of hospital and 
fatality statistics are less likely to suffer this bias and yet still 
corroborate the data. The demography of the drivers is an 
important consideration when planning effective prevention 
campaigns.
Risks associated with drugs: results from experimental 
studies and epidemiological risk studies
Although a drug may be found in the blood, it does not 
always follow that the influence of the drug was the cause of 
the accident. Two different methods are being used in current 
research to define the likelihood of drugs adversely affecting 
driving and therefore increasing the probability of causing or 
being otherwise involved in an accident; experimental and 
epidemiological studies.
Experimental studies measure the influence of drugs on 
driving performance using a large range of different tests 
(assessing psychomotor and cognitive functions): a drug 
is administered in different doses to volunteers and the 
effects on performance are measured and compared with 
those of a placebo-treated group or other positive control 
group (for example, alcohol). In this type of study, both the 
acute and chronic effects of the administered drug may be 
estimated. The effects of drugs vary with dose and route 
of administration, as well as with the susceptibility and 
tolerance of the user.
Experimental studies focusing on cannabis indicate that this 
drug has detrimental effects on driving ability (cognitive 
and psychomotor skills) and that most of these effects are 
dose-dependent. The combination of cannabis and alcohol 
results not only in the prolongation and enhancement of 
effects (decrease in lateral control) but also causes additional 
impairment (for example, lack of attention to traffic at the 
side). For benzodiazepines, depending on the type (long-
acting, medium-acting, short-acting), a correlation between 
dose and degree of impairment of memory or of psychomotor 
performance has been demonstrated (EMCDDA, in press).
Using epidemiological data to conduct case control studies, 
the risks associated with consumption of drugs can also be 
assessed: the risk of being involved in a traffic accident while 
driving under the influence of a drug and, more importantly, 
the risk of being responsible for such an accident. In the 
first calculation, the number of people involved, injured or 
killed in a traffic accident who are found to be drug positive 
(cases) are compared with the number of persons who are 
positive in the general driving population (control group). 
In the second calculation, the study investigates if there is 
an association between driving under the influence of drugs 
and responsibility for a traffic accident. Thus, these studies 
compare the prevalence of drugs in drivers who were 
responsible (cases) for an accident with the prevalence of 
drugs among drivers who were involved in one but were not 
responsible for it (control group). Some of the prevalence 
studies mentioned above came to conclusions about the 
impact of drug-taking on driving skills, based on behavioural 
and/or medical observations.
In Denmark, in the roadside study of 1 000 drivers, 
despite limited knowledge about the link between drug 
concentrations in saliva and those in blood, it was estimated 
that the results indicated reduced road safety in about half 
of the drivers who tested positive. A similar conclusion was 
reached by the Institute of Forensic Medicine when the saliva 
samples from 333 injured drivers were analysed to determine 
if the concentrations of drugs found could be considered 
to have influenced driving ability. In half of the positive 
samples, the concentrations were judged to indicate that 
drug taking had somehow contributed to the accident.
In France, a study comparing 900 drivers with 900 control 
subjects (2) found that, among drivers under the age of 27, 
driving under the influence of cannabis alone (> 1 ng/ml) 
was associated with a relative risk of an accident of 2.5. 
For the same group, driving under the influence of cannabis 
and alcohol (> 0.5 g/l) resulted in a relative risk of 4.6. For 
all drivers, regardless of age, driving when testing positive 
for benzodiazepines was associated with a relative risk of 
1.7. However, assumptions about accident risk based on 
these findings alone are of limited use because of a lack of 
information about the representativeness of the drivers’ and 
control patients’ samples.
(1)
(2)  A total of 900 drivers involved in a non-fatal accident were compared with 900 patients (control) who attended the same emergency units 
for non-trauma reasons.
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As part of the Immortal project, injury risk associated with 
drug use has been computed in the Netherlands; it found that 
no significantly increased risk of injury was associated with 
the use of cannabis when taken alone.
Single-vehicle accidents are becoming a focus of studies on 
driver culpability, as in such cases there is a high probability 
that the driver was at fault. In Norway, blood samples 
from drivers killed in single-vehicle accidents were studied 
in 1989–90 (n = 79) and 2001–02 (n = 92). The most 
frequently detected substances, apart from alcohol, were 
benzodiazepines (primarily diazepam, flunitrazepam) and 
THC, with amphetamines more prominent in the more recent 
study.
The only recent study in Europe that specifically calculated 
the risk of being responsible for a traffic accident while 
driving under the influence of drugs was performed in France 
between 2001 and 2003 on all drivers involved in a fatal 
crash. The results found a positive association between 
causing an accident and testing positive for cannabis, and 
a dose effect (see box ‘Cannabis in France’). The risk of 
causing an accident is considerably higher when cannabis 
is combined with alcohol (a relative risk of 14 has been 
estimated).
Situation analysis — summary
An illustration of the size of the problem relies on the 
prevalence studies available. Although many countries 
reported various study results or statistics involving alcohol 
and ‘drugs’, not so many were able to comment separately 
on the relative prevalence of cannabis and benzodiazepines. 
Cyprus, Lithuania, Poland and Portugal (3) did not provide 
any research that showed the relative extent of the use of 
these substances in their countries.
From an examination of the prevalence studies that have 
taken place throughout Europe since the mid-1990s 
(roadside, suspicion, injury/accident, hospital and involving 
fatalities), it is clear that, excluding alcohol, cannabis and 
benzodiazepines are the psychoactive substances most 
prevalent among the driving population. The results appear 
to be the same whatever the study setting, and which of the 
two is the most prevalent appears to be distributed relatively 
equally among studies. There are a few exceptions: in 
drivers in the far north, in Finland, Sweden and Latvia (and 
to a lesser extent Norway), amphetamines are frequently 
found; in Spanish drivers, cocaine is more prevalent than 
any other substance; and in drivers in Slovenia, opioids are 
found more than benzodiazepines. In addition, minor studies 
from Italy and Slovakia, with small sample sizes, have found 
cocaine and opioids respectively to be more prevalent than 
benzodiazepines. These findings have implications for public 
safety, for detection methods and for prevention policies.
Results from experimental studies show that consumption 
of both substances results in impairment of driving ability 
that may vary according to dose, tolerance and delay after 
Cannabis in France
One study not yet mentioned in this special issue is that 
which took place in France, the results of which were 
published at the end of 2005 (Laumon et al., 2005). It has 
not been mentioned up to now because its terms of reference 
did not give equal weight to measuring the prevalence of 
both cannabis and benzodiazepines (1), but nevertheless 
it is ground-breaking in its preparation, size, quality of 
study design and conclusions regarding the prevalence of 
cannabis use and its effects in drivers. In order to ensure the 
comprehensive representation of the national population in 
this study, a law was passed in 1999 making it obligatory 
for all drivers involved in a fatal accident to be tested for 
cannabis, amphetamines, opioids and cocaine. The SAM 
study is a population-based case–control study that analysed 
more than 17 000 accidents and almost 11 000 drivers 
involved in fatal accidents between September 2001 and 
September 2003. It was based on a quasi-exhaustive sample 
of road accidents (all the instantly fatal accidents that took 
place during the two years studied) and included drivers who 
were killed, injured or unhurt. A total of 6 766 drivers were 
considered to be responsible for a crash; the control group 
comprised 3 006 other drivers involved in accidents during 
the period.
The research found that 7 % of drivers tested positive for 
cannabis (blood THC level of more than 1 ng/ml), rising 
to 17 % among the under-25s. The effects of driving with a 
blood THC level of 1 ng/ml or higher increased the risk of 
being responsible for a (fatal) accident by 1.8 times overall 
(compared with 8.5 times for those with no THC but a blood 
alcohol concentration of 0.5 g/l or higher).
Knowing that the risk of accidents is higher in some age 
groups as a result of their behaviour, the risk of being 
responsible was calculated separately by age range among 
the control group. The chance of causing an accident was 
clearly higher in people aged 14 to 24 (1.9 times) and 
70+ (2.6 times).
The sample also permitted a calculation of the risk of dying in 
an accident even if the driver was not responsible for it; this was 
considered to be 1.5 times above average for a driver under 
the infl uence of cannabis (compared with 4 times for alcohol).
(1)  The sample was screened for benzodiazepines only if it was primarily 
positive for another drug.
(1)
(3) Two studies are ongoing in Portugal.
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intake. Recent risk assessment studies are rare in Europe, 
and their results are contradictory when taking into account 
cannabis or benzodiazepines alone; however, when these 
substances are considered together or in association with 
alcohol, the risk of being involved in or responsible for a 
traffic accident increases significantly (EMCDDA, in press).
It is also not clear whether drivers who test positive for 
benzodiazepines are using these drugs licitly or illicitly. 
In Austria, Sweden and Finland, analyses found that 
blood concentrations were frequently at therapeutic 
levels, whereas in Norway they were clearly higher. The 
identification of more than one drug in a single sample, 
e.g. benzodiazepines with THC or amphetamines, suggests 
misuse. Contrasting inferences about the users could be 
drawn from the various age/gender profiles identified.
However, the studies identify an additional problem for 
any evidence-based policy of road safety. Whilst medical 
science tries to find an efficient and effective rapid 
screening technique for cannabis or benzodiazepines, 
and to determine an appropriate cut-off level for legal use, 
comparable to a blood alcohol concentration, a large 
number of the above studies report that the substances are 
not used in isolation — polydrug use is common, with various 
combinations of various drugs and/or alcohol. Research into 
the effects of combining either cannabis or benzodiazepines 
with alcohol has demonstrated that there is a multiplier effect 
(Laumon et al., 2005; EMCDDA, in press). This can only add 
further confusion to any calculation of impairment.
Policy and legislation
Whether prompted by statistical evidence or media 
anecdotes, the issues of drugs and road travel have received 
increased attention at a high level in recent years. The most 
visible changes have been in national legislation, or in 
national strategies, either road safety strategies or strategies 
against drugs. In this section, these changes will be examined 
both generally, and also with a focus on particular laws or 
strategies that address the problems posed by cannabis and 
benzodiazepines specifically.
Laws and penalties
General legal changes to the prosecution of drug driving, 
and the penalties for it, have been made in a number 
of countries. Zero tolerance laws for illicit drugs such 
as cannabis were introduced in Belgium, Portugal and 
Sweden in 1999, and in France and Finland in 2003. The 
Swedish and Finnish laws also apply to medicines such as 
benzodiazepines when consumed without a lawful medical 
prescription. The changes in Belgium and France were 
the results of national studies, although in France popular 
pressure contributed to the law being passed before the 
study was completed. In Finland and Sweden, the new laws 
were based on the observation that the number of drivers 
under the influence of drugs being involved in accidents was 
growing, but the offence of impaired driving was extremely 
difficult to prosecute. In Cyprus, this problem continues, 
but is addressed by prosecuting such drivers for illegal 
consumption of drugs — an option specifically prohibited in 
the Belgian and United Kingdom laws, for example. A law 
drafted in Luxembourg and under discussion since 2003 
foresees possible zero tolerance for illicit substances and an 
increased fine.
Since 2000, penalties for the offence have been increased 
in the Czech Republic, Greece, Italy, Lithuania, and Latvia, 
and the Ministry of Justice is reviewing the current penalties 
in Denmark. In Slovakia, the new penal code strengthens the 
offence of endangerment, which may also be used for this 
subject.
Roadside testing
To facilitate rapid detection, a considerable number of 
countries have recently passed laws to allow or define 
roadside drug testing, for example by saliva or sweat testing. 
Such laws were passed in Italy, Poland and the United 
Kingdom in 2003, Slovenia in 2004, the Czech Republic, 
Latvia and Austria in 2005, Lithuania in 2006, and Portugal 
in 2007. Draft laws have also been prepared or discussed 
in Luxembourg, the Netherlands and Slovakia, some since 
2003, but await reliable test kits before enactment. The 
feasibility of roadside saliva testing is under consideration 
in Spain and Ireland. Such testing increasingly is obligatory; 
for example, since 2005, in Spain and the United Kingdom, 
drivers who are involved in an accident but fail to provide a 
sample have received penalty points on their licence, and in 
Latvia refusal to be tested has been a criminal offence since 
2006. Use of roadside testing equipment is also foreseen in 
the Cyprus national drug strategy 2004–08.
With or without such test kits, national authorities are also 
recognising the need to train law enforcement officers, 
particularly those on traffic duties, to recognise the symptoms 
of drivers who may be under the influence of drugs. 
This need is acknowledged in the Czech national drugs 
action plan of 2005–06, the Lithuanian road traffic safety 
programme 2005–10, the Austrian road safety programme 
of 2002–10 and the United Kingdom’s road safety 
strategy 2000–10.
Data collection
As authorities acknowledge the need to monitor the situation 
more closely, a number of changes have been made or 
proposed at national level.
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The law passed in 1999 in France made it obligatory to 
test for drugs all drivers involved in a fatal accident (i.e. 
even if it was not the driver who was killed), thus giving 
comprehensive data for the SAM study discussed above; it 
is perhaps remarkable in that a national law was passed 
specifically in order to assist a research project. In 2004, 
an order of the chief of police in Poland instructed that 
drivers involved in fatal accidents be tested. The Portuguese 
regulation currently mandates routine screening for drivers 
injured in an accident, or under suspicion, but an aim of 
the national plan of prevention and road safety 2003 is for 
routine controls of drivers involved in accidents or exhibiting 
dangerous driving. The draft law in Luxembourg also 
foresees systematic testing in accidents resulting in injuries. 
The Austrian law of 2002 introduced mandatory blood tests 
if there was suspicion. In Ireland, since 2002 the medical 
bureau of road safety has routinely tested all samples under 
the blood alcohol concentration limit; previously, this was 
done only on request.
Prevention strategies
Prevention measures are also legislated or foreseen at 
national level, commonly either in driving schools or in 
the medicinal sphere. In fact, actions addressing both 
feature in the Czech road safety strategy and the Slovakian 
national plan for increasing road safety 2005–10. The 
Italian road safety plan 2003–05 promotes training of 
driving school operators in drug-driving issues, and the 
collaboration agreement for the prevention of traffic 
accidents, drawn up between the Spanish Ministries of 
Interior and Health and Consumer Affairs, considers 
prevention by appropriate driving qualifications as a 
top priority. In Sweden, it has been proposed that drug-
awareness training should be a compulsory part of the 
driving licence course.
A decree in France in 2005 introduced clear pictograms 
on medicinal packaging, and several decrees of the State 
Council oblige doctors to provide full and appropriate 
information to patients about the risks of secondary 
effects of any medicine prescribed. In Portugal, the 
Directorate-General for Traffic plans to implement a 
system of pictograms for medicine labelling. Although a 
law in Sweden in 2005 abolished the existing pictogram 
system, due to inconsistencies, an earlier law of 1997 
obliges the doctor, prescriber and pharmacy to warn a 
patient of the effects of a medicine. In Norway, Ministry of 
Transport proposals made in 2006 included the need for 
better information to be given by prescribing doctors and 
pharmacists.
Policy and legislation — summary
Countries have reacted at the highest level to the possible 
threats posed by psychoactive drugs in drivers, with recent 
legislative and policy developments clearly visible in all 
areas. Illicit drugs such as cannabis are the subject of new 
zero-tolerance laws, whereas psychoactive medicines such as 
benzodiazepines are more often permitted provided they do 
not impair the user. Prevention actions are being mandated 
that separately target young people and users of medicines. 
New laws define the data collection systems, with the aim of 
informing the policy and refining it in future.
Nevertheless, there is a great variation in individual 
countries’ legal responses to drug-driving, between zero-
tolerance or impairment laws, and the range of penalties 
available to the judiciary across Europe remains remarkably 
wide. For a more detailed overview of the scope and 
penalties of Member States’ legislation on drugs and driving, 
see the ELDD topic overview (http://eldd.emcdda.europa.
eu/?nnodeid=5036).
Law enforcement procedures
Drafting and passing national legislation is one stage of the 
policy response process, but implementing it is not always 
easy, and this certainly seems to be the case in the emerging 
field of drug-driving. This section attempts to identify the 
commonalities of and differences in the procedures laid 
down for (traffic) police, doctors and laboratories, as the 
criminal justice system aims to apprehend and prosecute 
those drivers found to be driving after taking drugs, with a 
focus on any differences in detection procedures for cannabis 
and benzodiazepines in each country.
Although information on the areas below was not always 
provided by the countries, it is clear that various typologies 
exist between them. The first stage of contact between 
the driver and the law is usually the (traffic) police officer, 
who may need to attempt to establish if drug use has taken 
place. This process will be framed by some form of rules of 
procedure. Some countries have the detection procedures 
established by law (Belgium, Latvia), regulation (Lithuania, 
Luxembourg, Slovenia, Sweden) or guidelines (Czech 
Republic, United Kingdom). In a few countries (4), detection 
procedures should take place in a certain order, with the 
next step taking place only if the previous one confirms a 
suspicion; others do not report this hierarchy of tests. The 
detection procedures as a whole are broadly comparable, 
with observations and behavioural tests being followed by 
urine and blood samples, but what appears to differ is their 
location and the person executing them.
(1)
(4) Belgium, the Czech Republic, Austria, Portugal, Slovenia, Sweden.
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Progress towards mandatory testing of drivers involved 
in fatalities?
To increase knowledge of the situation, the European 
Commission’s expert working group on drugs, medicines 
and driving recommended in 2002 that all drivers involved 
in a fatal accident should be tested for alcohol and drug use. 
Some, but not all, countries report that testing is mandatory 
or systematic in certain situations involving fatal accidents, 
injuries, or even suspicion. In Poland and Finland, drivers 
involved in fatal accidents must be tested. Testing drivers 
involved in an accident that caused injury is reported as 
systematic in Denmark, Portugal and Norway (serious 
injury), and is proposed in the draft law in Luxembourg. Drug 
testing when there is suspicion is reported to be systematic 
in Estonia, France (in cases of physical harm), Ireland, Latvia 
and Slovakia (after an accident). There is some variance 
as to whether involvement in an accident is grounds for 
suspicion.
Nevertheless, a legal obligation for testing is not always 
easy to enforce nationally. Of the abovementioned countries 
listing systematic testing, Denmark, Estonia, Ireland and 
Portugal report that a drug test will not be carried out 
routinely if the driver is found to be over the blood alcohol 
concentration limit, as in terms of cost and evidence required 
for prosecution there is no reason for such a test. During a 
multicountry study of all drivers killed in 2001 and 2002, 
the percentage of toxicological analyses of such cases were 
96 % and 92 % in Sweden and Finland respectively, 70 % 
in Norway, but only 17 % in Denmark (Christophersen, 
2006) (consistent with the policy mentioned above). 
A 1993 study in Norway showed that blood samples for 
drug and alcohol analysis were secured from less than 
10 % of drivers involved in accidents resulting in personal 
injury, and improvement since then is reported to be 
unlikely. In Portugal, in 2001, about 25 % of drivers having 
accidents were not even checked for alcohol, although 
the national legislation prescribes a compulsory analysis 
in case of accident resulting in injuries or other damages; 
this is attributed to the lack of communication between law 
enforcement officers and practitioners in hospitals. In the 
Czech Republic, approximately 50 % of the people killed in 
traffic accidents were tested toxicologically in 2003–05.
Testing at random or on suspicion?
The primary distinction between detection procedures 
appears to be the legal ability to test at random or only in 
case of suspicion. However, at the side of a busy road, three 
issues appear to be interconnected at the beginning of the 
detection procedure. These are the result of a positive alcohol 
test; the authority of law enforcement to perform random 
drug testing; authorisation for use of rapid screening devices 
(usually for oral fluid).
Rapid roadside drug testing, for example by saliva or sweat 
testing, is legally permitted in the Czech Republic, Italy, 
Lithuania, Latvia, Austria, Poland, Slovenia and the United 
Kingdom, and draft laws have been under consideration 
in recent years in Luxembourg, the Netherlands, Slovakia, 
and Portugal. However, the two Rosita projects have been 
unable to recommend a screening device suitable for such 
a purpose (see box ’Roadside testing for drug use’), and so 
most countries that have taken part in these tests report that 
they will not use such devices yet. Other forms of roadside 
screening, for example the Belgian tests for physical signs, 
and then an immunoassay of a urine sample, may take 
30 to 45 minutes to perform for each driver.
Roadside testing for drug use
In humans, hair is the ‘long-term metabolic memory’ of 
what has been consumed, and urine is a shorter-term index. 
However, many laws require proof that the person was 
actually impaired at the time of driving, as opposed to proof 
of past drug consumption. The fi rst Rosita project in 1999–
2000 established criteria for acceptable tests (sensitivity and 
specifi city > 90 %, accuracy > 95 %) for amphetamines, 
benzodiazepines and cannabis. As rapid screening in 
a roadside situation should aim to be as non-invasive as 
possible, the Rosita-2 project aimed to evaluate the usability 
and analytical reliability of nine on-site oral fl uid (saliva) 
drug testing devices between 2003 and 2005. Six European 
countries and four states in the USA took part.
At the end of the period, none of those devices met the 
criteria proposed during the Rosita-1 project. Six devices 
registered a failure rate of greater than 25 %. The procedure 
for obtaining the saliva samples varied greatly in terms of 
handling, quantities and acceptance by offi cials testing 
and persons tested, sometimes easy to perform, sometimes 
diffi cult to follow. Another problem found was that smokers 
and amphetamine users produce less saliva, and so there 
were diffi culties in obtaining the necessary sample quantities 
in a reasonable time interval. As samples are temperature- 
dependent, it was also stated that ‘… use of some devices in 
cold and rainy weather was a problem’. Thus, at the end of 
the study ‘no device was considered to be reliable enough in 
order to be recommended for roadside screening of drivers’.
The authors therefore recommended that government offi cials 
should carefully weigh the pros and cons when considering 
introduction of random roadside drug testing. Further 
development and laboratory analytical work was seen as 
necessary to improve this method of multiple substance 
screening.
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At the same time, a number of countries report that a drug 
test will not routinely be carried out if the driver is found to 
be over the blood-alcohol concentration limit, as, in terms of 
evidence required for prosecution, there is no reason for such 
a test. The cost is also a factor; in Austria, following a two-
step screening, a subject still considered impaired must pay 
the cost of the subsequent blood test, which is approximately 
EUR 500.
Thus, for practical purposes, truly random drug tests of 
drivers by police are likely to remain theoretical for the 
moment, whether or not permitted in a country’s laws, and 
tests will most likely be carried out on those drivers who 
arouse suspicion because of their behaviour or appearance, 
whether as a result of committing a traffic offence or during 
a random stop and check for alcohol. Random tests may 
also be carried out in areas with a high likelihood of positive 
results, such as near discos or nightclubs on weekend nights.
Behavioural tests and medical observations
With the lack of a universally accepted roadside test kit, 
different countries have different procedures to identify an 
impaired driver. In some, a considerable amount of testing is 
carried out by the police themselves; in others, the police will 
refer the driver to medical staff to carry out similar (as well as 
more thorough) tests.
Training police to recognise impairment
As already stated, the first point of detection will usually 
be the police. With this in mind, in February 2002, the 
European Commission expert working group on drugs, 
medicines and driving recommended mandatory training 
of police involved in traffic control, to recognise signs 
of impairment due to drugs. These tests may include 
examination of the size of the eyes, coordination tests, 
behavioural tests, reactions, manner of speaking, etc. In the 
United Kingdom, the Department for Transport investigated 
the utility of the Field Impairment Test (FIT), a five-step 
procedure, by roadside officers, and found use of FIT had 
an accuracy of 66 % (i.e. the proportion of cases correctly 
identified as being drug free or drug positive). And in 
Norway, the police achieve high accuracy of recognition 
(approximately 80 % of those suspected), though they 
believe that benzodiazepines, in particular, may be difficult 
to detect, and so have expressed a wish for detection 
equipment.
Countries in Europe report various levels of training: 
obligatory, ad hoc or only general training. They can be 
summarised as follows:
Obligatory training — only trained officers are permitted 
to carry out the examination of drivers (Belgium, Portugal, 
Sweden, the United Kingdom).
Ad hoc training — various supplementary training 
programmes are reported for traffic police (Latvia, Lithuania, 
Luxembourg, Austria, Poland, Slovakia, Norway).
General — all officers, traffic or otherwise, receive basic 
training to recognise signs of drug consumption/impairment 
(Spain, Cyprus, Hungary, the Netherlands).
Behavioural tests leading directly to blood tests
Three countries, Belgium, the Netherlands and Sweden, 
reported that the results of behavioural tests carried out by 
the police could lead the latter to call directly for a blood 
test. In Belgium and Sweden, the basis for testing is laid 
down in the regulations (and, as described above, should be 
carried out only by specifically trained officers), whereas in 
the Netherlands the justification for testing is not specified: 
police officers are expected to follow their basic training 
to recognise the use of drugs and medicines. In Sweden, if 
behaviour and breath testing give rise to the suspicion of 
drug-taking, the first test is an eye examination, whereas 
in Belgium a battery of tests is available, consisting of tests 
for physical signs, concentration and behaviour (Romberg, 
finger to nose, etc.).
Behavioural tests with medical confirmation
The majority of countries report that police carry out certain 
behavioural tests but that further examination should be 
carried out by a medical professional — usually in medical 
premises — before blood samples are taken. These police 
tests appear to fall into two subgroups, general and specific. 
Countries which rely on general or non-standardised police 
observations of behaviour to send a driver for further 
examination include the Czech Republic, Denmark, Spain, 
Greece, Italy, Lithuania and Slovakia.
By contrast, other countries require their police to complete 
specific forms or tests before referring the driver to a 
medical professional. In Austria and Finland, traffic officers 
complete a drug-checking form, which may include questions 
about driving behaviour, the accident situation, responses, 
disposition, manner of speaking and walking as well as the 
results of the alcohol test. Tests in Portugal and Norway are 
similar, and in the United Kingdom qualified police officers 
will carry out the five-step field impairment test. In Slovenia, 
police must check the eyes for specified abnormalities.
Medical staff who carry out subsequent tests may also use 
similar standardised procedures.
Blood and urine samples
Location of sample deliveries
Following a behavioural test, urine and/or blood samples may 
be taken. Although not all countries gave this information, the 
information available from the reporting countries suggests 
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some differences in where these samples can be taken. This 
could be important, for example, in rural areas.
In Belgium, the urine sample may be ordered by the police 
at the roadside, but in other countries the urine sample will 
probably be taken at the same time as the blood sample in a 
non-roadside location. In Austria, the blood sample must be 
brought to the nearest police station without undue delay. In 
Luxembourg, the Netherlands, and Sweden, samples should 
be taken at a police station, whereas in other countries 
samples must be taken at some sort of health facility: medical 
premises in France (hospital, doctor’s surgery, clinic), 
a healthcare institution in Lithuania, a public hospital in 
Portugal. In Hungary, urine samples can be taken at police 
official rooms or any other room that suffices for this purpose, 
whereas blood samples can be taken either in police official 
rooms or in medical rooms, but only by a professional 
(accredited doctor).
Laboratory procedures and results
Blood and urine samples will be sent to laboratories for 
testing by various chemical analysis methods, the most 
common being gas chromatography–mass spectrometry 
(GC–MS).
Not many countries reported official threshold values 
for an offence, and those that did reported somewhat 
different thresholds. In Belgium, the level of cannabis in a 
blood sample from a driver that constitutes an offence is 
2 ng/ml. In France, the minimum detection threshold of 
THC in a blood sample is set at 1 ng/ml, below which the 
presence of drugs is judged as insignificant (uncertainty in 
measurement). In Portugal, the legal limit for blood is zero, 
but for urine is 50 ng/ml for cannabis and metabolites. 
In Germany, a 2005 recommendation based on a meta-
analysis recommended setting the limit value for the 
THC concentration in the blood at 3.5–5 ng/ml (lower 
if combined with alcohol); this followed a January 2005 
ruling by the Constitutional Court that 1 ng/ml would be a 
reasonable cut-off for zero tolerance (5). In Finland, no clear 
limit was reported for benzodiazepines, but the measuring 
ranges for pharmaceuticals hazardous to traffic safety 
have been set to cover the concentration levels at which 
each pharmaceutical has been proven to impair driving 
ability. Similarly, a committee appointed by the Norwegian 
Ministry of Transport and Communication recently proposed 
the setting of fixed limits for some of the most frequently 
occurring illicit and medicinal substances, which could save 
considerable police and judicial resources.
However, many countries reported that the decision as to 
whether an offence has been committed would be left to the 
medical professionals (or the judge who read the medical 
reports), based on both the amount found in the blood and 
the results of the behavioural tests. This is perhaps to be 
expected when many countries operate an ‘impairment’ 
principle, and do not penalise the presence of the substance 
in the blood per se, but the fact that the individual was no 
longer in a fit state to drive.
A few countries reported different laboratory procedures for 
cannabis and benzodiazepines. In France, in certain situations, 
the current system allows for urinary screening for illicit drugs, 
including cannabis. If the screening is positive (immediate 
result), or if a urine test is refused or impossible, a blood sample 
is taken and sent to a laboratory. Within the framework of this 
system, testing for possible consumption of benzodiazepines 
is carried only out in the event of a positive result for an illicit 
drugs test, via the examination of the blood sample taken.
In Finland, a case-specific expert statement is issued on the 
results of laboratory analyses, signed by a chemist. When 
pharmaceuticals or high concentrations of drugs are found, 
an expert physician also signs the statement. The laboratory 
cannot know whether a person has a prescription for the 
detected pharmaceutical. Therefore, any such findings will 
include the following text: ‘If the driver is not entitled to use 
the aforementioned pharmaceuticals, zero tolerance for 
drugs may be applied.’
In Sweden, legislation in place since 1999 lays down a 
zero-concentration limit for driving with measurable amounts 
of controlled scheduled narcotics in the blood. Prescription 
narcotics are an exception if taken according to a certified 
personal prescription. However, a person with a prescription 
for a drug can be convicted if he or she has not been able to 
drive in a secure manner.
In Portugal, if the blood analysis detects certain illicit 
substances, including cannabis, this can be charged as an 
administrative offence, or a crime if the driver was impaired 
and caused danger. Discovery of benzodiazepines or other 
medicines will result in a criminal conviction only if, following 
a medical evaluation, the driver had been considered 
impaired.
All countries that reported on the role of legal evidence 
(France, Luxembourg, Hungary, Poland, Portugal, Slovenia, 
Finland) stated that only the results of the blood test would 
be accepted, or urine tests in certain cases. Although rapid 
roadside testers had been authorised for use by the traffic 
police in most of these countries, they are to be used only as 
auxiliary screening devices. However, in Austria, the Vienna 
Social Fund has voiced concerns that a driver’s licence 
may be revoked immediately if a urinalysis and clinical 
examination indicate that the driver was impaired, although 
(1)
(5) http://stopthedrugwar.org/chronicle-old/371/germany.shtml
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the blood test result, available two weeks later, might not 
confirm impairment.
Law enforcement statistics
Law enforcement statistics for the offence of driving after 
taking psychoactive drugs — as distinct from alcohol — 
were provided for Denmark (sentences), Estonia (police 
detection), France (offences concerning illicit substances), 
Italy (infractions), Latvia (detained drivers), Lithuania (drivers 
registered and drivers prosecuted), Luxembourg (penalties 
given), the Netherlands (enrolment for prosecution), Austria 
(police reports, licences revoked), Poland (blood tests sent 
for analysis, blood tests proved to be DUID), Slovenia 
(expert examinations ordered by the police), Hungary 
(‘revealed crimes committed’) and Sweden (‘convictions 
and consequences’). By contrast, law enforcement statistics 
only for impaired driving, with no distinction between 
made between figures for drugs or alcohol, were reported 
by Ireland and the United Kingdom (sentencing), and in 
Slovakia, the statistics only record figures for alcohol.
Statistics recorded by the criminal justice systems, on police 
reports/arrests, prosecutions or convictions, did not give an 
insight into which drug was most frequently used by drivers, 
whether cannabis, benzodiazepines or others. Although 
the majority of countries reported police report/arrest, 
prosecution or conviction statistics for the offence of impaired 
driving, only Belgium provided statistics that identified which 
drug had been involved, and then only for THC (which, as a 
zero- tolerance offence, is a different legal offence to driving 
while impaired by a medicine). In 2000–04, 2 984 zero 
tolerance offences were sent to the judicial authorities, of 
which 54 % were based on THC. Finland and Norway 
reported the statistics kept at the National Institute of Public 
Health (number of blood tests carried out and the results), 
therefore results are available by drug.
The law enforcement statistics of the Czech Republic, 
Germany, Estonia, France and Lithuania (in this case also 
including alcohol) also included the number of accidents, 
cases of damage and deaths caused by driving under the 
influence of a substance.
Law enforcement — summary
From the above information, it seems that random stopping 
and drug testing of drivers throughout Europe is still some 
way off; there remain considerable differences between 
countries. This is partly due to the laws (even random breath 
testing for alcohol is only just approaching a pan-European 
policy) and partly because of the limitations of technology. 
The use of saliva-testing devices is being treated with caution, 
as their accuracy is limited at present. Without such objective 
devices, specialised training of traffic police to recognise 
the signs of drug impairment in drivers is increasing but 
remains somewhat sporadic in most countries; mandatory 
training, which is recommended, remains rare. At the present 
time, without the benefit of reliable technology, police at the 
roadside are not expected to distinguish which particular 
drug (or combination of drugs) may be affecting the driver.
Medical behavioural tests, by trained police or by medical 
staff, are becoming more sophisticated and standardised, 
judging from the countries that provided details on the issue. 
In the laboratory, more blood tests are requested and cut-offs 
are being established, though it is illustrative of the scientific 
debate surrounding the topic that the cut-off levels differ so 
greatly among only a few countries. There is also the issue 
of storing meaningful data from the above tests; recording 
that ‘a drug’ was involved will not aid policy-making when 
there are various classes of drug to test for/prevent. Fourteen 
countries (6) did not distinguish between drugs in their regular 
official statistics.
One thing on which the vast majority of countries agreed 
is that impairment is penalised, whatever the substance 
involved. Whether or not detection procedures differ 
according to whether the suspected substance is cannabis 
or benzodiazepines is determined mainly by the legal 
framework of the country. Whether there is zero tolerance for 
drug use or only those people who are impaired should be 
punished is also reflected in the use of blood analysis results 
and behavioural tests to convict a driver.
Prevention approaches and programmes
The above prevalence studies confirm the need for prevention 
techniques to reduce driving after taking drugs, but such 
needs can also be derived from the declared intentions of 
people to drive under the influence of drugs, or from their 
lack of knowledge about the consequences. For example, 
in Belgium, people in recreational settings were asked 
questions on driving risks. In 2004, 15 % of the respondents 
who had already used an illegal drug during the event 
declared that they would drive themselves back home, 
rising to 29 % the following year. Meanwhile, in Denmark, 
qualitative interviews for the Immortal project revealed a lack 
of awareness about the influence of illicit drugs on driving 
ability, about the effect of combining several drugs and/or 
alcohol and, among people who had retired early, about 
prescription medicines. In Cyprus, qualitative information 
collected by the traffic control department of the police 
revealed lack of awareness of the impairment and other 
consequences of driving under the influence of cannabis and 
(1)
(6)  The Czech Republic, Denmark, Ireland, Spain, Italy, Cyprus, Lithuania, Hungary, the Netherlands, Austria, Poland, Portugal, Slovenia, Slovakia and Sweden 
(though, of these, Lithuania and Poland state that their monitoring will include such distinctions in future).
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benzodiazepines, and in Poland a survey of 1 161 drivers 
questioned in 2001 about driving and prescription drugs 
found that only a quarter knew that the law does not allow 
driving under the influence of those drugs mentioned 
(e.g. benzodiazepines) (Florek et al., 2002).
Media coverage of the problem is reported to be visible only 
in France, Luxembourg, Sweden and the United Kingdom. 
In France and Luxembourg, this currently focuses on illicit 
drugs such as cannabis, rather than benzodiazepines, 
whereas Sweden and the United Kingdom report no focus 
on any particular substance. Sporadic coverage, usually 
in association with young people and alcohol, is more the 
norm, as noted in Germany, Cyprus, Austria, Poland and 
Slovakia.
Mass media campaigns
Since 1999 the majority of countries have carried out mass 
media campaigns involving the distribution of leaflets and 
posters and the construction of websites that describe the 
health risks of drug abuse and driving. Usually they focus 
on alcohol, though some, such as www.dont-drug-and-
drive.de established by the Association of German Insurers, 
are drug-specific. An exceptional approach was to focus on 
the illegality of such driving, stating the laws and penalties, 
as done in France for cannabis. Most campaigns could 
be grouped according to the drugs highlighted and target 
audiences. Some were aimed at the general public and some 
were aimed at schools, recreational settings and medicines. 
Research suggests that, as consumers come from different 
socioeconomic classes and age groups, a ‘one size fits 
all’ campaign may not be the most effective (Siebers et al., 
2003); older benzodiazepine users will apparently ignore 
messages aimed at young cannabis users, and vice versa, 
while neither will feel that warnings about alcohol apply to 
them.
Nine countries reported publicity campaigns, which could 
be grouped into those aimed at general users, school 
pupils, frequenters of recreational settings and users of 
pharmaceuticals. General campaigns were reported 
in Belgium, Austria, Portugal and the United Kingdom. 
Campaigns were run in schools in Belgium, the Czech 
Republic, Luxembourg, Austria and Poland, whereas 
campaigns outside schools but aimed at young people 
took place in France, Sweden and the United Kingdom. 
Campaigns targeting pharmaceutical drugs or their users 
were carried out in Belgium, Austria, Portugal and the United 
Kingdom.
Future campaigns are also foreseen in the Czech Republic, 
as part of the Road Safety Strategy, for consumers of 
alcohol and medicines; in Lithuania as part of the Road 
Traffic Safety Programme generally; and in Slovakia as part 
of the National Plan for Increasing Road Safety targeting 
the use of alcohol and other psychotropic substances in 
general, and to provide information about pharmaceuticals. 
Campaigns are also planned in the Netherlands, to 
be aimed at young men, and in Portugal, regarding 
pharmaceuticals.
Driving schools
A number of prevention programmes are carried out in 
driving schools. In Germany, the project FreD (EDDRA 
database) uses peer trainers to inform young adults in the 
course of their driving instruction about the risks of driving 
under the influence of alcohol and drugs, as does Peer Drive 
Clean, an EU-funded project in 11 European countries. Both 
driving school instructors, who often have problems with 
addressing the subject in the theoretical part of their training, 
and learners, who appreciated the opportunity to talk openly 
about the risks and consequences of drink- and drug- driving 
with peers of their age, generally rated the project positively 
in the evaluation survey.
In Spain, a project in driving schools in the Galician 
autonomous region (EDDRA database) involves 
discussions with psychologists; and in Valladolid driving 
school instructors are being taught by teachers from the 
Faculty of Medicine. In Italy, also, under the National 
Road Safety Plan for 2003–05, two workshops were 
created to train instructors and develop a package 
for driving school teachers. Driving instructors were 
also trained in Austria, and classes in driving schools 
regarding the influence of substances on driving are now 
mandatory in Poland and Sweden. For the future, the 
Czech Republic has identified as a priority interventions 
in driving schools focusing on the effects of medicines and 
psychoactive substances.
In Luxembourg, drivers whose licences have been suspended 
can recover them by taking part in programmes that include 
awareness raising on the effects of alcohol, medicines and 
drugs on driving.
Youth, peer and community approaches
As well as the peer trainers in driving schools mentioned 
above, programmes involving direct intervention by peers 
are reported in Belgium, Luxembourg and Portugal. In 
Belgium and Luxembourg, the NGO Responsible Young 
Drivers (RYD) scheme, run by volunteers aged 17–29, attends 
various events and offers saliva tests to young people to 
detect cannabis and amphetamines use. If the test is positive, 
drivers are free to decide whether or not to drive home. Also, 
in Portugal, free breath, urine and saliva tests are available 
at special events.
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One community approach is programmes to encourage, 
or even provide, a ‘designated driver’, who would stay 
sober for the night. These took place in Belgium, Germany, 
Spain, Estonia, France, Latvia, Lithuania, Luxembourg, 
the Netherlands and Poland as part of the European 
Designated Driver Campaign supported by the European 
Commission (7) (Euro-BOB/NESA). In Portugal, the national 
motoring association offers a 24-hour service (at a cost) 
whereby the driver and car can be brought home, and in 
Germany the 50–50 Taxi project is available to disco-goers 
in Saxony-Anhalt, who can take a taxi home at half price 
on Friday and Saturday nights; the other half of the cost is 
paid by sponsors from industry (Ministerium für Gesundheit 
und Soziales Sachsen, 2006, personal communication). 
Separately, many German cities have introduced additional 
bus routes at night, hourly or on demand for disco-goers, 
after the end of regular operating hours, though these are 
rare in rural areas. A night bus system has also been recently 
introduced in Luxembourg.
As in other fields of prevention, the production and 
dissemination of information material seems to be the 
predominant approach, and many projects focus mostly 
on awareness and consciousness raising, solely through 
education. However, their effectiveness is usually measured 
by user appreciation surveys, and only rarely by observing 
actual changes in behaviour.
Labelling and prescription of medicines
Clear information given to patients may prevent those 
taking psychoactive medicines from driving while adversely 
affected. The majority of countries rely on information on 
a possible effect on driving being printed in the patient 
information leaflet inside the packaging. The use of a clear 
symbol or pictogram on the packaging of medicines that 
may affect driving ability is currently reported by only five 
countries: Denmark, France, the Netherlands, Slovakia and 
Finland. In Austria, ‘information’ should be given on the 
outside of the packaging, and in the Czech Republic the 
ordinance on medicinal preparations permits it, but it is only 
used exceptionally. The Czech Republic and France report a 
three-tier classification system of differing degrees of danger.
A red warning triangle was placed on the outside of 
packaging of psychoactive medicines in Sweden, but the 
pictogram was removed in 2005 because of inconsistencies 
in labelling and the risk that patients might not be aware of 
the effect of the medicine on driving skills if there was no 
warning triangle. The triangle was replaced with a written 
description of the possible impact on driving skills enclosed 
with the medicine.
Nevertheless, it is not always clear what concentrations 
merit care, or how many hours after taking the medicine 
must elapse before the patient is safe to drive. Although 
the ultimate responsibility may well rest with the patient 
(‘if you feel drowsy, do not drive’), it is known that subjective 
experiences of fitness to drive often do not correlate with 
objective performance measures. For example, patients 
who take benzodiazepines to treat anxiety tend to report 
feeling much better, even though these drugs objectively 
cause impairment. Patients who take benzodiazepines as 
an hypnotic in the evening will clearly feel the effect prior to 
falling asleep, but have repeatedly reported to feel normal 
and alert in the morning, whereas objective driving tests did 
show subtle but clinically relevant impairment.
The other method of delivery of information is via doctors and 
pharmacists. Prescribing doctors must inform patients of the 
risks associated with medicines in Germany, Luxembourg, 
Poland and the United Kingdom, whereas in France, Sweden 
and Finland both the doctor and the pharmacist are bound 
to inform the patient of any risks. In France, doctors may be 
obliged to prove that they have provided their patients with 
full and appropriate information about the risks (even highly 
unlikely risks) of secondary effects linked to the medical 
treatments given or prescribed.
Prevention — summary
Not all countries reported comprehensive details of 
prevention actions, but from the examples described here 
it would seem there is a certain bias towards actions 
targeted at young people. School campaigns, driving school 
campaigns and campaigns in discos and nightclubs feature 
prominently, a logical response to the number of young 
people who die in traffic accidents in Europe every weekend 
night, whether through alcohol, drugs or spur-of-the-moment 
risk-taking. The majority of prevention programmes reported 
usually addressed alcohol, or simply ‘alcohol and drugs’, 
but the effectiveness of such ‘one size fits all’ campaigns 
has been challenged. Some actions are being taken to 
target users of psychoactive medicines, but these seem 
to be rather rare. Considering the demographic findings 
reported here, in addition to actions targeting the young, 
countries could perhaps also keep in mind the older segment 
of the population, who may use psychoactive medicines for 
legitimate reasons but are not aware of the possible effects 
they may have.
(1)
(7) http://ec.europa.eu/transport/roadsafety/publications/projectfiles/nesa_en.htm
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Conclusion
Cannabis and benzodiazepines are perhaps the two most 
significant psychoactive substances consumed by drivers in 
Europe, apart from alcohol. However, the average profile of 
consumers, detection methods and the settings of prevention 
measures (nightclubs and schools compared with doctors 
and pharmacists) are very different for the two drugs. 
Public perceptions of the dangers of each substance do not 
necessarily reflect scientific evidence, and the correction of 
these perceptions is crucial to the success of future prevention 
initiatives.
The above studies suggest that drug use in the general 
population does not always correlate with use among the 
driving population. To obtain an accurate picture of the 
prevalence of driving under the influence of drugs, rather than 
of drug use in the previous week, studies should distinguish 
between active principles found in blood and metabolites in 
urine. In the case of benzodiazepines, scientists are beginning 
to assess the effects of short-acting, medium-acting and long-
acting benzodiazepines in terms of implications for road safety. 
Personal susceptibility and tolerance developed with longer-
term use are also factors to consider. Prevention programmes 
focus on young people but some have started to address users 
of prescription medicines. The danger of impairment by either 
illicit drugs or medicines is greatly increased when alcohol is 
consumed at the same time. Polydrug use among drivers is a 
phenomenon that demands increased attention.
Although much is being done to address the problem of drug-
driving in general, and national laws are being tightened 
and penalties increased, responses are rarely targeted at 
cannabis and benzodiazepines. Behavioural tests for use 
by police are being designed, evaluated and improved, 
though the training of traffic police in these tests seems to be 
rather sporadic. Some criminal justice statistics are recorded 
to monitor the situation, though not always to the level of 
detail that could inform future policies. With regard to illicit 
drugs such as cannabis, it can be unclear as to whether the 
law prohibiting drug use in drivers is part of road safety 
policy or of policy regarding the control of illicit drugs. In the 
case of medicines such as benzodiazepines, there remains 
discussion in certain quarters as to the trade-off between 
protecting society by penalising those driving under the 
influence and permitting normal mobility for individuals who 
may not be able to function without such medication — some 
benzodiazepines are anticonvulsants, for example. But the 
legal status is clear in almost every country in Europe: driving 
while impaired by benzodiazepines, even if used correctly 
according to a prescription, is an offence.
International standards for research on drug-driving have 
been drafted, aiming to make future research comparable 
and permitting meaningful meta-analyses. These are being 
implemented to a large extent in the European Commission’s 
four-year EUR 24 million DRUID project; it remains to be 
to seen if this project confirms the results found above, or 
provides evidence for different conclusions.
Finally, the matter should be always kept in proportion. 
Although studies were requested for this report to compare 
and contrast cannabis and benzodiazepines in drivers, from 
the data submitted there is no doubt that the number one 
substance endangering lives on European roads today is 
alcohol.
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